ITEMS IN AFP WITH KEYWORD:
Mar 1, 2019 Issue
Pharmacologic Treatment of Borderline Personality Disorder [FPIN's Help Desk Answers]
There is no pharmacotherapy regimen that improves the overall symptoms of borderline personality disorder. When used for six months or less, antipsychotics can improve paranoia, dissociation, mood lability, anger, and global functioning.
Neuropsychologists use standardized assessment tools to determine whether cognitive decline has occurred, differentiate neurologic from psychiatric conditions, and identify neurocognitive etiologies. Find out when neuropsychological evaluations can be helpful for patients with dementia, mild cognitive impairment, traumatic brain injury, or other conditions.
As reviewed here, the available evidence on gun violence prevention provides some options to consider incorporating into family physicians' practices.
As part of the Deprescribing Guidelines in the Elderly Project, a Canadian team consisting of two family physicians, one geriatric psychiatrist, two geriatricians, and four pharmacists has provided recommendations to guide physicians in deprescribing antipsychotics for behavioral and psychological symptoms of dementia and insomnia.
Although a patient’s capacity to make medical decisions is usually assessed intuitively, there may be times when a more formal assessment is needed. Find out which tools are best for evaluating a patient’s decision-making capacity, when to seek consultation with a psychiatrist, and when a surrogate decision maker should be consulted.
Jun 1, 2018 Issue
Atypical Antipsychotics for Disruptive Behavior Disorders in Children and Adolescents [Cochrane for Clinicians]
Risperidone reduces measures of aggression and improves conduct in children with disruptive behavior disorders; however, only short-term use is recommended. Weight gain of 2 to 2.5 kg (4.4 to 5.5 lb) is common. There is insufficient evidence to evaluate the benefits of other antipsychotics.
Hypnosis provides small to moderate improvements in surgical pain and burn debridement pain in adults.
What are the benefits and harms of treatments for adults with binge-eating disorder?
Jan 1, 2017 Issue
Extended-Release Bupropion for Preventing Seasonal Affective Disorder in Adults [Cochrane for Clinicians]
When started in the fall, extended-release bupropion, 300 mg once daily, is effective in preventing recurrent symptoms in high-risk adults with a history of SAD (number needed to treat [NNT] = 5), as well as those at lower risk (NNT = 8). Headaches, nausea, and insomnia may limit adherence to treatment.
Dec 1, 2016 Issue
Aripiprazole vs. Placebo or Haloperidol for Schizophrenia [Medicine by the Numbers]
Aripiprazole was shown to have one major benefit over placebo, but favorable outcomes with haloperidol throw its effectiveness into question. Are the differences merely anomalies?